This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today

NEW YORK (TheStreet) -- Tekmira Pharmaceuticals (TKMR - Get Report) shares are up 11.5% to $15.90 on Monday in response to the FDA's announcement that it "stands ready" to work with companies fighting an outbreak of Ebola that has killed over 700 people in six months.

The stock is trading on heavy volume with 6 million shares changing hands in early trading, well ahead of its three month daily average of 390,980 shares.

This announcement raises hopes for Tekmira's TKM-Ebola Phase 1 Ebola treatment, which the agency placed a clinical hold on last month.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The hold means that the company cannot continue the same clinical trial that the FDA stopped, but the company could propose a new trial.

A senior official at the FDA told Reuters that "the agency would consider proposals for providing treatments under special emergency new drug applications" if the proposed treatment landed on the right side of the agency's cost-benefit analysis.

Analysts at TheStreet believe that investors buying Tekmira stocks in anticipation of benefiting from the potential increased demand may be betting on the wrong horse.

TKMR ChartTKMR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
TKMR $11.58 -0.43%
AAPL $125.78 -0.52%
FB $87.89 0.69%
GOOG $523.03 -0.07%
TSLA $279.15 -0.31%

Markets

DOW 17,691.83 -38.28 -0.22%
S&P 500 2,070.21 -6.57 -0.32%
NASDAQ 4,992.4390 -16.7750 -0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs